Artgen Biotech PJSC (MIC:ABIO) Scaled Net Operating Assets: 0.62 (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIC:ABIO Artgen Biotech PJSC MIC:ABIO
17 GF Score
Price ₽44.46
View Full Analysis

What is Artgen Biotech PJSC Scaled Net Operating Assets?

Artgen Biotech PJSC MIC:ABIO +0.50% 17 Scaled Net Operating Assets is 0.62 as of Jun. 2023. GuruFocus rates MIC:ABIO with a GF Score™ of 17/100.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Artgen Biotech PJSC's operating assets for the quarter that ended in Jun. 2023 was ₽1,988 Mil. Artgen Biotech PJSC's operating liabilities for the quarter that ended in Jun. 2023 was ₽731 Mil. Artgen Biotech PJSC's Total Assets for the quarter that ended in Dec. 2022 was ₽2,045 Mil. Therefore, Artgen Biotech PJSC's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2023 was 0.62.


Artgen Biotech PJSC Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Artgen Biotech PJSC's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artgen Biotech PJSC Scaled Net Operating Assets Chart

Artgen Biotech PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.54 0.56 0.57 0.64

Artgen Biotech PJSC Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.57 0.57 0.64 0.62

MIC:ABIO vs VRTX, REGN, SGEN: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Artgen Biotech PJSC's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artgen Biotech PJSC Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artgen Biotech PJSC's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Artgen Biotech PJSC's Scaled Net Operating Assets falls into.


MIC:ABIO
17GF Score
Artgen Biotech PJSC MIC:ABIO
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artgen Biotech PJSC Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Artgen Biotech PJSC's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2022 )
=(Operating Assets (A: Dec. 2022 )-Operating Liabilities (A: Dec. 2022 ))/Total Assets (A: Dec. 2021 )
=(1761.954-642.709)/1737.248
=0.64

where

Operating Assets(A: Dec. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2044.564 - 282.61
=1761.954

Operating Liabilities(A: Dec. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1474.309 - 712.738 - 118.862
=642.709

Artgen Biotech PJSC's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2023 )
=(Operating Assets (Q: Jun. 2023 )-Operating Liabilities (Q: Jun. 2023 ))/Total Assets (Q: Dec. 2022 )
=(1988.409-730.669)/2044.564
=0.62

where

Operating Assets(Q: Jun. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2355.516 - 367.107
=1988.409

Operating Liabilities(Q: Jun. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1542.353 - 711.16 - 100.524
=730.669

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.62 mean?
Artgen Biotech PJSC (MIC:ABIO) has a Scaled Net Operating Assets of 0.62 as of Jun. 2023. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Artgen Biotech PJSC and its competitors.
Is Artgen Biotech PJSC's Scaled Net Operating Assets too high?
Artgen Biotech PJSC's current Scaled Net Operating Assets is 0.62. Overall, Artgen Biotech PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Artgen Biotech PJSC's Scaled Net Operating Assets compare to VRTX and REGN?
Artgen Biotech PJSC's Scaled Net Operating Assets of 0.62 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Artgen Biotech PJSC and its competitors. Artgen Biotech PJSC's current Scaled Net Operating Assets is 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artgen Biotech PJSC stock overvalued right now?
Artgen Biotech PJSC (MIC:ABIO) has a current Scaled Net Operating Assets of 0.62. The current Scaled Net Operating Assets is 0.62. Artgen Biotech PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Artgen Biotech PJSC (MIC:ABIO), the current Scaled Net Operating Assets is 0.62 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artgen Biotech PJSC Business Description

Address Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
17GF Score

Get the complete analysis for MIC:ABIO

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₽44.46
Price